GlassScriptPhysician profile
Joseph C Lentini
NPI 1447226568
$451.02
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $111.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $130.69 | 2019-2020 | |
| Lilly USA, LLC | $47.34 | 2019-2020 | |
| Novo Nordisk INC | $38.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.20 | 2019 | |
| Glaxosmithkline, LLC. | $32.69 | 2020 | |
| Abbvie INC. | $31.00 | 2019 | |
| Indivior INC. | $28.89 | 2019 | |
| Pfizer INC. | $24.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.67 | 2020 | |
| Amarin Pharma, INC. | $14.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.13 | 2020 | |
| Orexo US, INC. | $11.45 | 2019 | |
| Allergan, INC. | $10.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lentini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.